{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:47:02Z","timestamp":1766551622276,"version":"3.40.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.neuropharm.2016.08.012","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T16:42:43Z","timestamp":1471279363000},"page":"449-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"PA","title":["Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-1195","authenticated-orcid":false,"given":"Gunasingh J.","family":"Masilamoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Uthayathas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella M.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.08.012_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.pscychresns.2013.08.011","article-title":"White matter metabolism differentiates schizophrenia and bipolar disorder: a preliminary PET study","volume":"214","author":"Altamura","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1176\/ajp.2007.164.7.1072","article-title":"Relative glucose metabolic rate higher in white matter in patients with schizophrenia","volume":"164","author":"Buchsbaum","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2009.07.015","article-title":"FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia","volume":"114","author":"Buchsbaum","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib4","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1523\/JNEUROSCI.20-22-08443.2000","article-title":"Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity","volume":"20","author":"Calabresi","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1126\/science.1066969","article-title":"A\u00a0paradigm shift in brain research","volume":"294","author":"Carlsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib7","first-page":"457","article-title":"Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates","volume":"25","author":"Casey","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1523\/JNEUROSCI.15-03-01704.1995","article-title":"Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms","volume":"15","author":"Colwell","year":"1995","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J.\u00a0Histochem Cytochem"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11846","article-title":"Concurrent activation of striatal direct and indirect pathways during action initiation","volume":"494","author":"Cui","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ilar.48.4.339","article-title":"Nonhuman primate models of Parkinson's disease","volume":"48","author":"Emborg","year":"2007","journal-title":"ILAR J."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","article-title":"The emerging role of glutamate in the pathophysiology and treatment of schizophrenia","volume":"158","author":"Goff","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00213-013-3371-7","article-title":"Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating","volume":"231","author":"Gresack","year":"2014","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85109","article-title":"Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity","volume":"4","author":"Hardingham","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.61.6_suppl_3.S4","article-title":"The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1176\/appi.ajp.162.5.931","article-title":"Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia","volume":"162","author":"Lehrer","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0896-6273(02)00828-0","article-title":"Function and regulation of CREB family transcription factors in the nervous system","volume":"35","author":"Lonze","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib21","doi-asserted-by":"crossref","first-page":"e00057","DOI":"10.1002\/prp2.57","article-title":"PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways","author":"Megens","year":"2014","journal-title":"Pharmacol. Res. Perspect. 2"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib22","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib23","first-page":"92","article-title":"Signal transduction abnormalities in schizophrenia: the cAMP system","volume":"36","author":"Muly","year":"2002","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1177\/0269881110372547","article-title":"Using MRI to measure drug action: caveats and new directions","volume":"25","author":"Murphy","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib25","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnana.2011.00043","article-title":"Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons","volume":"5","author":"Nishi","year":"2011","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/oxfordjournals.schbul.a033325","article-title":"Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters","volume":"24","author":"O'Donnell","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib28","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1523\/JNEUROSCI.1238-14.2015","article-title":"Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways","volume":"35","author":"Padovan-Neto","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ana.20279","article-title":"Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates","volume":"56","author":"Papa","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib61","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2011.02.005","article-title":"Radiosynthesis and in\u00a0vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A","volume":"38","author":"Plisson","year":"2011","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib31","doi-asserted-by":"crossref","unstructured":"Polito, M., Guiot, E., Gangarossa, G., Longueville, S., Doulazmi, M., Valjent, E., Herve, D., Girault, J.A., Paupardin-Tritsch, D., Castro, L.R., et\u00a0al. (2015). Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32(1,2,3). eNeuro 2..","DOI":"10.1523\/ENEURO.0060-15.2015"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2013.09.014","article-title":"Modeling Parkinson's disease in monkeys for translational studies, a critical analysis","volume":"256","author":"Potts","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.neuropharm.2009.11.011","article-title":"Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in\u00a0vivo","volume":"58","author":"Sammut","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A\u00a0possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2009.09.008","article-title":"Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A","volume":"58","author":"Strick","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JCP.0b013e318248da90","article-title":"Application of external review for subject selection in a schizophrenia trial","volume":"32","author":"Targum","year":"2012","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/bi00778a018","article-title":"Multiple cyclic nucleotide phosphodiesterase activities from rat brain","volume":"10","author":"Thompson","year":"1971","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biopsych.2013.08.025","article-title":"Neuroimaging biomarkers for early drug development in schizophrenia","volume":"76","author":"Tregellas","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-006-0439-7","article-title":"Dopaminergic modulation of striatal plateau depolarizations in corticostriatal organotypic cocultures","volume":"191","author":"Tseng","year":"2007","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2013.10.015","article-title":"Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications","volume":"77","author":"Uthayathas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneumeth.2013.02.004","article-title":"Assessment of adverse effects of neurotropic drugs in monkeys with the \u201cdrug effects on the nervous system\u201d (DENS) scale","volume":"215","author":"Uthayathas","year":"2013","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib48","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1523\/JNEUROSCI.4470-03.2004","article-title":"The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorded in\u00a0vivo","volume":"24","author":"West","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuropharm.2015.08.008","article-title":"Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum","volume":"99","author":"Wilson","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib50","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.4049\/jimmunol.154.4.1717","article-title":"Protein kinase C mediates activation of nuclear cAMP response element-binding protein (CREB) in B lymphocytes stimulated through surface Ig","volume":"154","author":"Xie","year":"1995","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2016.08.012_bib51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.08.012_bib52","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1523\/JNEUROSCI.3460-13.2014","article-title":"Selective expression of a dominant-negative type Ialpha PKA regulatory subunit in striatal medium spiny neurons impairs gene expression and leads to reduced feeding and locomotor activity","volume":"34","author":"Yang","year":"2014","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816303471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816303471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T21:47:27Z","timestamp":1718747247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816303471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":54,"alternative-id":["S0028390816303471"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.08.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}